Current Headlines

  1. Experimental Stem Cell Treatment Cleared For First Human Trial
    9/12/2014

    Japanese researchers at the RIKEN Center for Developmental Biology (CDB) have prepared a potential treatment using stem cells to treat degenerative eye diseases, and they are set to begin testing the treatment on the first human patient very soon.

  2. MabVax Links Arms With MSK, Juno For Anti-Cancer Drugs
    9/12/2014

    Clinical stage biotech firm MabVax Therapeutics announced that it has entered into partnerships with Memorial Sloan Kettering Cancer Center (MSKCC) and Juno Therapeutics to develop novel anti-cancer therapeutics using MabVax’s antibody discovery platform.

  3. Genmab And Seattle Genetics Expand ADC Collaboration
    9/12/2014

    Biotech firms Genmab and Seattle Genetics announced a new antibody-drug conjugate collaboration to create an ADC that will target AXL, a prominent signaling molecule on multiple solid tumors that plays a key role in tumor development and growth. Over the course of the partnership, Genmab and Seattle Genetics will co-develop HuMax-AXL-ADC, an ADC that combines an AXL-targeting, high affinity human monoclonal antibody with Seattle Genetics’ cytotoxic drug.

  4. Altor, Shenzhen Beike Enter Immunotherapy Agreement In China
    9/12/2014

    Altor BioScience, a U.S. firm developing novel cancer immunotherapies, and Shenzhen Beike Biotechnology, a Chinese cell-based therapy firm, announced that the companies have signed into a license agreement for the development and commercialization of immunotherapy ALT-803 in China.

  5. NeuroVive, OnCore BioPharma Sign $150M Licensing Agreement For HBV Infection Treatment
    9/11/2014

    Sweden based NeuroVive Pharmaceutial has just entered into an exclusive worldwide licensing agreement with U.S. biotech company OnCore BioPharma for the development and commercialization of NeuroVive’s drug candidate NVP018 for chronic Hepatitis B Virus (HBV) infection.

  6. Potential Treatment Discovered For Autoimmune Diseases
    9/11/2014

    Researchers at the University of Bristol have made an important breakthrough that could lead to new treatments for debilitating autoimmune diseases; they have discovered a process to 'switch off' these diseases. This discovery points to the use of antigen-specific immunotherapy as a treatment for many autoimmune disorders, including multiple sclerosis (MS), type 1 diabetes, Graves' disease, and systemic lupus erythematosus (SLE).

  7. New Rare Type Of Neuromuscular Disease Identified
    9/11/2014

    A rare new hereditary neuromuscular disorder has just been identified by an international team of researchers. The inherited condition is caused by a genetic mutation which affects the messages sent by nerves to control muscles, resulting in loss of muscle control and subsequent muscle weakening.

  8. Cempra Scores $10M Milestone From Toyama For Antibiotic Clinical Progress
    9/11/2014

    North Carolina based drugmaker Cempra announced on Tuesday that it has received a $10 million milestone payment from its Japanese partner, Toyama Chemical, following the clinical progress of its macrolide antibiotic, solithromycin.

  9. USPTO Issues Patent For GenSpera’s Prostate Cancer Prodrug
    9/11/2014

    GenSpera announced in a press release that the United States Patent and Trademark Office (USPTO) has issued a patent for its prostate cancer prodrug. Patent number 8,822,406, “Tumor Activated Prodrugs,” covers the prodrug’s composition. The new patent joins the 12 others patents that GenSpera owns or licenses, of which 10 relate to prostate cancer. Craig Dionne, PhD, GenSpera CEO, said, “The issuance of this patent further strengthens our intellectual property position for targeted anti-cancer prodrugs and recognizes their unique applicability in treating prostate cancer.”

  10. United Therapeutics Advances Phase I Trial Of PLX-PAD In PAH
    9/10/2014

    Pluristem Therapeutics, a company that develops placenta-based cell therapy products, announced that its licensing partner United Therapeutics is advancing the Phase I study of Pluristem's PLacental eXpanded (PLX-PAD) cells in patients with pulmonary arterial hypertension (PAH).